Citadel Advisors
IMVT icon

Citadel Advisors’s Immunovant IMVT Stock Holding History

Citadel Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.17M Buy
160,123
+15,725
+11% +$479K ﹤0.01% 4368
2026
Q1 		$3.59M Sell
144,398
-10,109
-7% -$262K ﹤0.01% 4918
2025
Q4 		$3.93M Sell
154,507
-592,046
-79% -$13.2M ﹤0.01% 4690
2025
Q3 		$12M Buy
746,553
+396,161
+113% +$6.41M ﹤0.01% 2990
2025
Q2 		$5.61M Buy
350,392
+22,567
+7% +$341K ﹤0.01% 3909
2025
Q1 		$5.6M Sell
327,825
-116,188
-26% -$2.43M ﹤0.01% 3694
2024
Q4 		$11M Buy
444,013
+104,092
+31% +$2.95M ﹤0.01% 2864
2024
Q3 		$9.69M Sell
339,921
-3,591
-1% -$106K ﹤0.01% 2942
2024
Q2 		$9.07M Buy
343,512
+115,013
+50% +$3.27M ﹤0.01% 2893
2024
Q1 		$7.38M Sell
228,499
-582,940
-72% -$21.3M ﹤0.01% 3368
2023
Q4 		$34.2M Sell
811,439
-33,937
-4% -$1.25M 0.01% 1495
2023
Q3 		$32.5M Buy
845,376
+539,527
+176% +$12.2M 0.01% 1435
2023
Q2 		$5.8M Sell
305,849
-860,027
-74% -$16M ﹤0.01% 3419
2023
Q1 		$18.1M Buy
1,165,876
+193,154
+20% +$3.35M ﹤0.01% 2027
2022
Q4 		$17.3M Buy
972,722
+901,589
+1,267% +$11.4M ﹤0.01% 2121
2022
Q3 		$397K Sell
71,133
-38,872
-35% -$190K ﹤0.01% 8955
2022
Q2 		$429K Sell
110,005
-114,586
-51% -$495K ﹤0.01% 8995
2022
Q1 		$1.24M Sell
224,591
-23,170
-9% -$144K ﹤0.01% 7216
2021
Q4 		$2.11M Buy
247,761
+79,018
+47% +$652K ﹤0.01% 6106
2021
Q3 		$1.47M Sell
168,743
-6,669
-4% -$60.2K ﹤0.01% 7138
2021
Q2 		$1.85M Sell
175,412
-384,929
-69% -$5.37M ﹤0.01% 6791
2021
Q1 		$8.99M Sell
560,341
-208,693
-27% -$5.5M ﹤0.01% 3140
2020
Q4 		$35.5M Buy
769,034
+67,959
+10% +$3.14M 0.01% 1237
2020
Q3 		$24.7M Buy
701,075
+487,423
+228% +$14.7M 0.01% 1394
2020
Q2 		$5.2M Buy
213,652
+195,896
+1,103% +$4.2M ﹤0.01% 3027
2020
Q1 		$276K Buy
+17,756
New +$267K ﹤0.01% 7482

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's IMVT Position: Q2 2026 in Review

Citadel Advisors increased its Immunovant (IMVT) stake by 11% in Q2 2026, buying an estimated $479K and bringing the position to 160,123 shares worth $6.17M. The position accounts for ﹤0.01% of the portfolio, ranked #4368.

Citadel Advisors first reported a position in IMVT in Q1 2020 and has held it in 26 quarters since. The position peaked at $35.5M in Q4 2020. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Citadel Advisors held 160,123 shares of Immunovant worth $6.17M as of Q2 2026.
  • Citadel Advisors bought 15,725 Immunovant shares in Q2 2026, an estimated $479K.
  • Immunovant made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4368 holding.
  • Citadel Advisors first reported a position in Immunovant in Q1 2020 and has held it in 26 quarters since.
  • Citadel Advisors's Immunovant position peaked at $35.5M in Q4 2020.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.